Alto Neuroscience Announces That The Phase 2b Study Of ALTO-100 In Patients With Major Depressive Disorder Did Not Meet Its Primary Endpoint, Assessed By A Change From Baseline In Montgomery-Åsberg Depression Rating Scale, Compared To Placebo
Portfolio Pulse from Benzinga Newsdesk
Alto Neuroscience announced that its Phase 2b study of ALTO-100 for Major Depressive Disorder did not meet its primary endpoint, as measured by the Montgomery-Åsberg Depression Rating Scale, compared to placebo.
October 22, 2024 | 8:32 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Alto Neuroscience's Phase 2b study of ALTO-100 did not meet its primary endpoint, which could negatively impact investor sentiment and the stock price.
The failure to meet the primary endpoint in a clinical trial is typically seen as a negative outcome, which can lead to a decrease in stock price due to reduced investor confidence in the product's future success.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100